6.10-6.16 | 临床研究顶刊快报
文摘
教育
2024-06-17 10:58
中国香港
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
1. Hamilton MP, Sugio T, Noordenbos T, et al. Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. New England Journal of Medicine. 2024;390(22):2047-2060. doi:doi:10.1056/NEJMoa24013612. Aaron SD, Vandemheen KL, Whitmore GA, et al. Early Diagnosis and Treatment of COPD and Asthma — A Randomized, Controlled Trial. New England Journal of Medicine. 2024;390(22):2061-2073. doi:doi:10.1056/NEJMoa24013893. Ozdemirli M, Loughney TM, Deniz E, et al. Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy. New England Journal of Medicine. 2024;390(22):2074-2082. doi:doi:10.1056/NEJMoa24015304. Neumann JT, Twerenbold R, Weimann J, et al. Prognostic Value of Cardiovascular Biomarkers in the Population. JAMA. 2024;331(22):1898-1909. doi:10.1001/jama.2024.55965. Feng X, Zahed H, Onwuka J, et al. Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening: A Systematic Review and Meta-Analysis. JAMA. 2024;331(22):1910-1917. doi:10.1001/jama.2024.58146. Coutts SB, Ankolekar S, Appireddy R, et al. Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial. The Lancet. 2024/06/15/ 2024;403(10444):2597-2605. doi:https://doi.org/10.1016/S0140-6736(24)00921-87. Chan K, Wahome E, Tsiachristas A, et al. Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study. The Lancet. 2024/06/15/ 2024;403(10444):2606-2618. doi:https://doi.org/10.1016/S0140-6736(24)00596-88. Yang K, Yang X, Jin C, et al. Global burden of type 1 diabetes in adults aged 65 years and older, 1990-2019: population based study. BMJ. 2024;385:e078432. doi:10.1136/bmj-2023-078432 9. Zhu Y, Zhang W, Dimagli A, et al. Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial. BMJ. 2024;385:e075707. doi:10.1136/bmj-2023-075707部分文字参考新英格兰医学前沿。
